

# References

## I-9171

1. Ocrevus prescribing information. Genentech, Inc. August 2022.
2. Multiple Sclerosis Coalition. The Use of Disease Modifying Therapies in Multiple Sclerosis: Principals and Current Evidence. Updated June 2019. National Multiple Sclerosis Society. Available at: [https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT\\_Consensus\\_MS\\_Coalition.pdf](https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf).
3. Institute for Clinical and Economic Review (ICER). Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value. March 6, 2017. Available at: [https://icer-review.org/wp-content/uploads/2016/08/CTAF\\_MS\\_Final\\_Report\\_030617.pdf](https://icer-review.org/wp-content/uploads/2016/08/CTAF_MS_Final_Report_030617.pdf).
4. Rae-Grant, Alexander, MD, et al. Practice Guideline Recommendations Summary: Disease-Modifying Therapies for Adults with Multiple Sclerosis. *Neurology*. 2018;90:777-788.
5. Corboy, John R, MD, et al. Comment on 2018 American Academy of Neurology Guidelines on Disease-Modifying Therapies in MS. *Neurology*. 2018;90:1106-1112.
6. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria. *Lancet Neurol* 2018; 17:162-73.
7. National Multiple Sclerosis Society 2017 McDonald MS Diagnostic Criteria. Available at: <https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Diagnosing-MS/Diagnosing-Criteria>.
8. MS international federation. Types of MS. Last updated 12th March 2022. Accessed at Types of MS |Multiple Sclerosis (msif.org).
9. Lichtenstein G. R., Loftus E. V., Isaacs K. L., Regueiro M.D., Gerson L. B., Sands B. E. ACG clinical guideline: management of Crohn's disease in adults. *The American Journal of Gastroenterology*. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27.

10. Conway D, Cohen JA. Combination therapy in multiple sclerosis. *Lancet Neurol* 2010 Mar;9(3):299-308.
11. Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. *The Can J Neurol Sci.* 2020;47:437-455.
12. Kitzler HH, Wahl H, Eissel JC, et al. Multi-component relaxation in clinically isolated syndrome; Lesion myelination may predict multiple sclerosis conversion. *NeuroImage: Clinical* 20 (2018)61-70.
13. Lichtenstein G. R., Loftus E. V., Isaacs K. L., Regueiro m. D., Gerson L. B., Sands B. E. ACG clinical guideline:management of Crohn's disease in adults. *The American Journal of Gastroenterology.* 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.
14. MS international federation. About MS - Symptoms. Accessed at MS Symptoms |Multiple Sclerosis (msif.org).
15. National Institute for Health and Care Excellence. NICE Guidance - Conditions and diseases - Neurological conditions -Multiple sclerosis. Ofatumumab for treating relapsing multiple sclerosis. Technology appraisal guidance [TA699} Published:19 May 2021. Accessed at 3 Committee discussion |Ofatumumab for treating relapsing multiple sclerosis |Guidance |NICE.